|
|
Blood, 15 September 2006, Vol. 108, No. 6, pp. 1835-1840.
Prepublished online as a Blood First Edition Paper on May 18, 2006; DOI 10.1182/blood-2006-02-004325.
 Previous Article | Next Article 
Submitted February 17, 2006
Accepted May 2, 2006
Survival Benefit with Imatinib Mesylate versus Interferon Alpha-Based Regimens in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Hagop M. Kantarjian*, Moshe Talpaz, Susan O'Brien, Daniel Jones, Francis Giles, Guillermo Garcia-Manero, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Jianqin Shan, and Jorge Cortes
Departments of Leukemia,University of Texas M. D. Anderson Cancer Center
Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center
Departments of Leukemia, U.T. MD Anderson Cancer Center
Hematopatology, University of Texas M. D. Anderson Cancer Center
Departments of Leukemia, University of Texas M. D. Anderson Cancer Center
Departments of Leukemia,, University of Texas M.D. Anderson Cancer Center
Departments of Leukemia, The University of Texas M.D. Anderson Cancer Center
Departments of Leukemia,, University of Texas - M. D. Anderson Cancer Center
Departments of Leukemia,, The University of Texas M.D. Anderson Cancer Center
Departments of Leukemia,, UT MD Anderson Cancer Center
* Corresponding author; email: hkantarj{at}mdanderson.org.
A survival benefit for imatinib mesylate versus interferon- therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML) due to the high rate of cross over (90%) from interferon- to imatinib within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib at our institution (2000 - 2004) to 650 patients treated with interferon- (1982 - 1997). The complete cytogenetic response rates were 87% with imatinib and 28% with interferon- (p < 0.0001). The estimated 3-year survival rates were 96% with imatinib and 81% with interferon- (p < 0.01). Survival rates with imatinib were significantly better than with interferon- within each of the CML prognostic risks groups. By multivariate analysis, imatinib therapy was identified as an independent favorable prognostic factor, after accounting for the impact of pretreatment factors (hazard ratio 0.04; p < 0.01). By landmark analysis at 12 months, survival within each cytogenetic response category was similar with imatinib or interferon-, suggesting that the survival benefit of imatinib (versus interferon- in newly diagnosed CML) is through improving cytogenetic response.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Jabbour, D. Jones, H. M. Kantarjian, S. O'Brien, C. Tam, C. Koller, J. A. Burger, G. Borthakur, W. G. Wierda, and J. Cortes
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Blood,
September 3, 2009;
114(10):
2037 - 2043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, J. Shan, D. Jones, S. O'Brien, M. B. Rios, E. Jabbour, and J. Cortes
Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response
J. Clin. Oncol.,
August 1, 2009;
27(22):
3659 - 3663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, J. E. Cortes, and H. M. Kantarjian
Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
Mayo Clin. Proc.,
February 1, 2009;
84(2):
161 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bixby and M. Talpaz
Imatinib As Frontline Therapy for Patients with Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia
ASCO Educational Book,
January 1, 2009;
2009(1):
395 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. de Lavallade, J. F. Apperley, J. S. Khorashad, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al.
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
J. Clin. Oncol.,
July 10, 2008;
26(20):
3358 - 3363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Blood,
February 15, 2008;
111(4):
1774 - 1780.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. White, V. A. Saunders, P. Dang, J. Engler, A. Venables, S. Zrim, A. Zannettino, K. Lynch, P. W. Manley, and T. Hughes
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Blood,
December 1, 2007;
110(12):
4064 - 4072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood,
October 15, 2007;
110(8):
2828 - 2837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes
Important Therapeutic Targets in Chronic Myelogenous Leukemia
Clin. Cancer Res.,
February 15, 2007;
13(4):
1089 - 1097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
